Regulation of Insulin-like Growth Factor I Receptor Dephosphorylation by SHPS-1 and the Tyrosine Phosphatase SHP-2 by Maile, Laura A. & Clemmons, David R.
Regulation of Insulin-like Growth Factor I Receptor
Dephosphorylation by SHPS-1 and the Tyrosine Phosphatase
SHP-2*
Received for publication, September 25, 2001, and in revised form, December 20, 2001
Published, JBC Papers in Press, January 4, 2002, DOI 10.1074/jbc.M109258200
Laura A. Maile and David R. Clemmons‡
From the Division of Endocrinology, University of North Carolina, Chapel Hill, North Carolina 27599
Activation of insulin-like growth factor I receptor
(IGF-IR) kinase is an important site of control of IGF-I-
linked intracellular signaling pathways. One potentially
important regulatory variable is IGF-IR dephosphoryl-
ation. It has been shown that SHP-2, a tyrosine phospha-
tase, can bind to the activated IGF-IR in vitro; however,
its role in IGF-IR dephosphorylation in whole cells is
unknown. These studies were undertaken to determine
whether SHP-2 was a candidate for mediating IGF-IR
dephosphorylation. The IGF-IR in smooth muscle cells
was dephosphorylated rapidly beginning 10 min after
ligand addition, and this was temporally associated with
SHP-2 binding to the receptor. IGF-I stimulated SHPS-1
phosphorylation and the subsequent recruitment of
SHP-2. In cells expressing a SHPS-1 mutant that did not
bind SHP-2 there was no recruitment of SHP-2 to the
IGF-IR. Cells expressing a catalytically inactive form of
SHP-2 showed SHP-2 recruitment to SHPS-1, but this
did not result in SHPS-1 dephosphorylation, and there
was a prolonged IGF-IR phosphorylation response after
IGF-I stimulation. These studies indicate that IGF-IR
stimulates phosphorylation of SHPS-1 which is critical
for SHP-2 recruitment to the plasma membrane and for
its recruitment to the IGF-IR. Recruitment of SHP-2 to
the receptor then results in receptor dephosphoryl-
ation. The regulation of this process may be an impor-
tant determinant of IGF-IR-mediated signaling.
The insulin-like growth factor I (IGF-I)1 receptor (IGF-IR) is
composed of two extracellular subunits and two transmem-
brane  subunits. Upon ligand binding, the kinase domain of
the receptor autophosphorylates several tyrosine residues that
are located in the intracellular domains of the  subunits (1–3).
This provides binding sites for other molecules, including in-
sulin receptor substrate 1 (IRS-1) and SHC (4, 5), and the
activated IGF-IR transmits downstream signals via tyrosine
phosphorylation of these molecules. Activation of these ty-
rosines is not only critical for the downstream signaling, but
also for sustained stimulation of IGF-I-stimulated biologic re-
sponses. Mutation of specific tyrosines in the receptor has been
shown to result in attenuation of the ability of IGF-I to stimu-
late DNA synthesis, cell migration, and inhibition of apoptosis
(6). Most important is the triple tyrosine motif that is phospho-
rylated rapidly in response to catalytic activation of the recep-
tor, and mutation of any of these residues results in loss of
signaling and IGF-I responsiveness (7).
The tyrosine phosphorylation status of proteins in growth
factor signaling pathways is maintained by a balance between
the activity of tyrosine kinases and tyrosine phosphatases.
Because phosphorylation of these tyrosines in the receptor 
subunit is so important for IGF-I signaling it has been assumed
that dephosphorylation of the receptor would result in appro-
priate regulatory control of this signaling stimulus. The time
course of phosphorylation of tyrosine kinase-containing growth
factor receptors has been shown to be biphasic with an early
peak resulting in activation of the signaling intermediates
within 0–10 min of ligand occupancy of the receptor followed by
a slower phase of receptor dephosphorylation usually proceed-
ing over the next 10–30 min. One candidate phosphatase for
dephosphorylation of the IGF-IR is the tyrosine phosphatase
SHP-2 (Syp, PTP-1D, SHPTP2). SHP-2 is a nontransmem-
brane phosphotyrosine phosphatase that contains two SH-2
domains (8, 9). It has been shown to bind to a number of growth
factor receptors including the IGF-IR (10, 11), the insulin re-
ceptor (10), and also to IRS-1 (12, 13); however, whether it
dephosphorylates the IGF-IR in whole cells has not been
determined.
Growth hormone (GH) activation of GH receptor has been
shown to result in binding of SHP-2 to the GH receptor and
tyrosine phosphorylation of SHP-2 (14–16). Mutation of tyro-
sine 595, which is required for SHP-2 binding, results in pro-
longed GH receptor phosphorylation, suggesting that SHP-2
activation contributes to dephosphorylation of the GH receptor
and GH receptor-mediated signaling (16). In addition to bind-
ing and interacting with SHP-2, activated GH, insulin, and
growth factor receptors have also been shown to stimulate the
phosphorylation of a transmembrane protein termed SHPS-1
(Sirp , Bit) (14, 17–20). After phosphorylation of two tyrosines
that are contained in the intracellular domain of SHPS-1,
SHP-2 is recruited from the cytoplasm to the plasma mem-
brane, and its binding to SHPS-1 activates its phosphatase
activity (18–20). Mutation of these tyrosines in SHPS-1 results
in the failure of SHP-2 to be recruited to the membrane (21).
The recruitment of SHP-2 to SHPS-1 has been shown to corre-
late with the negative effect of SHPS-1 on insulin signaling
(19), and in the case of the GH receptor, loss of SHP-2 recruit-
ment to SHPS-1 has been shown to result in prolonged GH
receptor phosphorylation (22). Based on these prior observa-
tions, we attempted to determine whether SHP-2 dephospho-
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rylates the IGF-IR after IGF-I-induced receptor activation, to
identify the role of SHPS-1 in recruitment of SHP-2 to the
activated receptor, and to determine the consequences of block-
ing this recruitment using mutagenesis.
EXPERIMENTAL PROCEDURES
Materials
Human IGF-I was a gift from Genentech (South San Francisco, CA).
Polyvinylidene difluoride filters were purchased from Millipore Corpo-
ration (Bedford, MA). Autoradiographic film was obtained from East-
man Kodak. Fetal bovine serum, Dulbecco’s modified Eagle’s medium,
penicillin. and streptomycin were purchased from Invitrogen. The
IGF-IR  chain antibody was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA). The polyclonal SHP-2 antibody and the monoclonal,
horseradish peroxidase-linked, phosphotyrosine antibody (RC20) were
purchased from Transduction Laboratories (Lexington, KY). Two
SHPS-1 polyclonal antibodies were used. The first was obtained from
Transduction Laboratories and was raised to the entire cytoplasmic
domain of SHPS-1 (SHPS-1fl) the second was raised our laboratory in
rabbits using a synthetic peptide containing the C-terminal 20 amino
acids of the SHPS-1 cytoplasmic tail as an immunogen (SHPS-1tr). All
other reagents were purchased from Sigma unless otherwise stated.
Porcine aortic SMCs (pSMCs) were isolated as described previously
(23) and maintained in Dulbecco’s modified Eagle’s medium supple-
mented with 4.5 g/liter glucose, 100 units/ml penicillin, 100 g/ml
streptomycin, and 10% fetal bovine serum in 10-cm tissue culture
plates. The cells were used between passage 5 and 16.
Methods
Generation of Expression Vectors—Full-length human SHP-2 and
SHPS-1 were cloned by reverse transcription-PCR from a cDNA library
that had been derived from human fibroblast mRNA (GM10, Human
Genetic Cell Repository, Camden, NJ). For SHP-2 the 5-primer se-
quence used corresponded to nucleotides 133–158 of the human SHP-2
sequence but with the addition, at the 5-end, of nucleotides encoding
the FLAG peptide. The 5-primer sequence was 5-ATG GAC TAC AAA
GAC GAC GAC GAC AAA ACA TCG CGG AGA TGG TTT CAC CCA
AA-3. The bases encoding the FLAG peptide are underlined. The
3-primer sequence used was complementary to nucleotides 1882–1911
and was 5-TCA TCT GAA ACT TTT CTG TTG CAT-3. After DNA
sequencing to confirm that the correct sequence had been amplified the
PCR product was subcloned into pMEP4 expression vector (Invitrogen).
To clone SHPS-1 the 5-primer sequence used corresponded to nucle-
otides 17–35 of human SHPS-1 (5-CAG CCG CGG CCC ATG GAG
CC-3), and the 3-primer sequence was complementary to nucleotides
1502–1524 (5-CAA ACC ACG GTC CCA TTC TGA-3). After DNA
sequencing to confirm that the correct sequence had been amplified the
PCR product was subcloned into the pMEP4 expression vector.
Generation of the Catalytically Inactive SHP-2—PCR was used to
incorporate a replacement of Cys459 by Ser in the catalytic site of SHP-2
(SHP-2 C-S). This mutation was shown previously to result in a domi-
nant negative catalytically inactive form of SHP-2 (23, 24). Two cDNA
fragments encoding the SHP-2 DNA were generated. The first fragment
was made using the same 5-primer as that used to clone full-length
SHP-2; the 3-primer was complementary to nucleotides 1474–1497,
but it also contained 3 additional bases at the 3-end of the DNA
sequence which introduced an HpaI cleavage site. The primer sequence
was 5-GTT * AAC GAC CGG CCC TGC ATC CAT GAT-3. The addi-
tional 3 bases are underlined, and the site of the HpaI cleavage is
marked *. The fragment was generated using a 5-primer sequence
corresponding to nucleotides 1498–1525, but it also contained a 3-base
extension at the 5-end to generate an SnaB1 cleavage site, and it
included 2-base substitutions (TGC-TCA) to encode the Cys459 3 Ser
mutation. The sequence was 5-TAC * GTA CAC TC#A# AGT GCT GGA
ATT GGCCGG A-3. The additional 3 bases are underlined, and the
point of SnaB1 cleavage is marked with *. The base changes encoding
the Cys3 Ser substitution are indicated with #. The 3-primer was the
same as that used to clone the full-length SHP-2.
The two PCR products were then cloned into the pcDNA 3.1 V5 His
vector (Invitrogen). After amplification the two fragments were di-
gested and separated from the vector. The first fragment was digested
at BamHI in the polylinker of the vector, 5 to the introduced DNA
sequence and at the introduced HpaI site. The second fragment was
digested at the Xho site in the vector polylinker sequence 3 to the
introduced DNA sequence and at the introduced SnaB1 site. The DNA
fragments were then ligated at the compatible blunt ends generated by
the HpaI and SnaB1 digestions, and the DNA sequence encoding the
full-length SHP-2 incorporating the Cys3 Ser substitution was cloned
into the pcDNA 3.1 V5 His vector. After amplification and sequencing
the modified sequence was subcloned into the pMEP4 expression
vector.
Generation of the Truncated Form of SHPS-1—PCR was used to
generate a truncated form of SHPS-1 (SHPS-1tr) that terminated at
amino acid 463 resulting in the loss of the two C-terminal tyrosine
residues (Tyr 449/Tyr475) that had been shown to be required for SHP-2
binding (23). The 5-primer used was the same as that used to clone the
full-length SHPS-1, and the 3-primer that was used was complemen-
tary to nucleotides 1390–1416 except that it contained base substitu-
tions to incorporate a stop codon at the end of the sequence (at position
1414–1416). The sequence was 5-CTA GGG CTG CGG GCT GGT CTG
AAT GCT-3. The introduced stop site is underlined. The modified DNA
sequence was cloned into the pcDNA 3.1 V5 His vector. After sequenc-
ing and amplification it was subcloned into the pMEP4 expression
vector.
Transfection of pSMCs—The pSMCs (passages 4 and 5) were trans-
fected with the various pMEP4 expression vectors. In all cases trans-
fections were performed using the poly-L-ornithine method as described
previously (24). Hygromycin-resistant pSMCs were selected and main-
tained in Dulbecco’s modified Eagle’s medium-H containing 15% fetal
bovine serum and 100 g/ml hygromycin. Transfected pSMCs were
used in subsequent experiments between passages 6 and 20.
Cell Lysis—Cells were incubated overnight in SFM and then exposed
to 100 ng/ml IGF-I for the appropriate length of time before lysis in
ice-cold lysis buffer (50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% Non-
idet P-40, 0.25% sodium deoxycholate, 1 mM EGTA, 1 mM sodium
orthovanadate, 1 mM sodium fluoride, 1 mM phenylmethylsulfonyl flu-
oride, 1 g/ml pepstatin A, 1 g/ml leupeptin, and 1 g/ml aprotinin).
The lysates were clarified by centrifugation at 14,000  g for 10 min.
Immunoprecipitation was then carried out as described below.
Immunoprecipitation—The supernatants were incubated overnight
at 4 °C with the appropriate antibody (IGF-IR, SHP-2, or SHPS-1 using
a 1:500 dilution). Immune complexes were then precipitated by adding
protein A-Sepharose and incubating for a further 2 h at 4 °C. The
samples were then centrifuged at 14,000  g for 10 min and the pellets
washed four times with lysis buffer. The pellet was resuspended in 45
l of reducing Laemmeli buffer, boiled for 5 min, and the proteins
separated by SDS-PAGE, 8% gel.
Western Immunoblotting—After SDS-PAGE the proteins were trans-
ferred to a polyvinylidene difluoride membrane. The membranes were
blocked in 1% bovine serum albumin in Tris-buffered saline with 0.1%
Tween (TBST) for 2 h at room temperature. The membranes were
incubated with one of four primary antibodies (IGF-IR, SHP-2, SHPS-1,
or RC20 all at a dilution of 1:500) overnight at 4 °C and then washed
three times in TBST. Binding of the peroxidase-labeled antibody was
visualized using enhanced chemiluminescence following the manufac-
turer’s instructions (Pierce) and either exposure to autoradiographic
film or detection using the GeneGnome CCD imaging system (Syngene
U. K. Ltd.).
Band intensities were measured by scanning densitometry and an-
alyzed using NIH Image, version 1.61. Student’s t test was used to
compare differences between treatments. The results that are shown
are representative of at least three separate experiments.
RESULTS
Time Course of IGF-IR Phosphorylation in Response to IGF-
I—After a 5-min stimulation of quiescent pSMCs with IGF-I
there was a 13  1-fold (mean  S.E., n  3) increase in IGF-IR
phosphorylation. After a 10-min treatment with IGF-I there
was a further 1.3  0.12-fold (n  3) increase in IGF-IR phos-
phorylation. By 20 min there was a 2.1  0.25-fold (n  3)
decrease in receptor phosphorylation compared with the level
of phosphorylation which is detectable at 10 min. A represent-
ative experiment in shown in Fig. 1.
Association of SHP-2 with the IGF-IR after IGF-IR Phospho-
rylation—In Fig. 2 it can be seen that there was little SHP-2
associated with the IGF-IR in the basal state and after 5 min of
IGF-I stimulation. However, after a 10-min stimulation there
was detectable SHP-2 association, and at 20 min there was a
marked 16  4.5-fold increase (n  3) in SHP-2 association
with the IGF-IR. These results suggest that there is a correla-
tion between the time at which the phosphorylation state of the
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IGF-IR is decreasing and the time at which the SHP-2 tyrosine
phosphatase association increases.
SHPS-1 Phosphorylation after IGF-I Stimulation—Because
SHP-2 is predominantly a cytosolic protein, it must be re-
cruited to the plasma membrane before it can bind to the
IGF-IR. The phosphorylation of SHPS-1 and its subsequent
recruitment of SHP-2 from the cytosol have been shown to be
stimulated by various growth factors. Fig. 3 shows that as with
other growth factors IGF-I stimulated a rapid increase in
SHPS-1 phosphorylation. Maximum IGF-I stimulated phos-
phorylation of SHPS-1 occurred after a 5-min incubation (6.6 
0.7-fold; n  3), and this was followed by a 2.6  1.1-fold (n 
3) decrease in SHPS-1 phosphorylation by 10 min.
Recruitment of SHP-2 to SHPS-1 after IGF-I Stimula-
tion—We next examined whether SHP-2 was recruited to
SHPS-1 after IGF-I-stimulated SHPS-1 phosphorylation. Fig. 4
shows that there was no detectable SHP-2 association with
SHPS-1 in the basal state, but SHP-2 was recruited to SHPS-1
after a 5-min exposure to IGF-I. The association of SHP-2 with
SHPS-1 decreases rapidly, and association is barely detectable
at 10 min.
Loss of SHP-2 Recruitment to SHPS-1 in Cells Expressing a
Truncated Form of SHPS-1—The recruitment of SHP-2 to
SHPS-1 and then its subsequent rapid disassociation sug-
gested that this was a potential mechanism by which SHP-2
could be recruited to the plasma membrane and then become
available to bind to the IGF-IR. The SHP-2 binding site on
SHPS-1 has been identified as the two C-terminal tyrosine
residues (23). To examine whether SHP-2 recruitment to
IGF-IR required that SHP-2 first be recruited from the cytosol
to SHPS-1 we expressed a truncated form of SHPS-1 which
lacked the two C-terminal tyrosine residues (SHPS-1tr) and
examined SHP-2 recruitment to both SHPS-1 and the IGF-IR
after IGF-I stimulation. Fig. 5A shows that after immunopre-
cipitation and immunoblotting with the SHPS-1 antibody
raised to the entire cytoplasmic tail, comparable levels of
SHPS-1 protein were detected in SHPS-1tr cells and in cells
transfected with the empty vector alone. However, Fig. 5B
shows that no SHPS-1 protein can be detected in cells express-
ing SHPS-1tr when the antibody raised to the C-terminal re-
gion of SHPS-1 was used to immunoblot, whereas abundant
SHPS-1 protein can be detected in cells transfected with the
empty vector alone. This suggests that the truncated form of
SHPS-1 is acting in a dominant negative manner.
In Fig. 5C it can be seen that despite levels of SHPS-1 protein
in the cells expressing SHPS-1tr comparable to levels in cells
expressing the empty vector, there was no recruitment of
SHP-2 to SHPS-1 in cells expressing the truncated form of the
protein, whereas cells transfected with the empty vector
showed abundant SHP-2 bound to SHPS-1 after 5 min of IGF-I
stimulation. This blot was exposed to film for 24 h to show that
there was no SHP-2 association in the cells expressing trun-
cated SHPS-1.
Loss of SHP-2 Recruitment to the IGF-IR in Cells Expressing
FIG. 1. IGF-IR phosphorylation time course. Cells were grown to
90% confluence and then incubated overnight in SFM. Cells were then
exposed to 100 ng/ml IGF-I for various lengths of time as indicated.
After cell lysis and immunoprecipitation (IP) with an anti-IGF-IR an-
tibody, tyrosine phosphorylation of the receptor was visualized by West-
ern immunoblotting (IB) with an anti-phosphotyrosine antibody. The
results are expressed as arbitrary scanning units: 2,132 (far left lane),
25,963 (second lane), 30,431 (third lane), and 11,699 (far right lane). To
control for loading inequities the amount of IGF-IR protein in each lane
is shown in the lower panel.
FIG. 2. SHP-2 association with the IGF-IR. Cells were grown to
90% confluence and then incubated overnight in SFM. They were then
exposed to 100 ng/ml IGF-I for various lengths of time as indicated.
After cell lysis and immunoprecipitation (IP) with an anti-IGF-IR an-
tibody the association of SHP-2 with the receptor was visualized by
Western immunoblotting (IB) with an anti-SHP-2 antibody. The results
are expressed as arbitrary scanning units: 1,104 (far left lane), 8,775
(second lane), 15,033 (third lane), and 27,114 (far right lane). To control
for loading inequities the amount of IGF-IR protein in each lane is
shown in the lower panel.
FIG. 3. SHPS-1 phosphorylation in response to IGF-I stimula-
tion. Cells were grown to 90% confluence and then incubated overnight
in SFM. They were then exposed to 100 ng/ml IGF-I for various lengths
of time as indicated. After cell lysis and immunoprecipitation (IP) with
an anti-SHPS-1 antibody, tyrosine phosphorylation was visualized by
Western immunoblotting (IB) with an anti-phosphotyrosine antibody.
The results expressed as arbitrary scanning units are: 2,961 (far left
lane), 10,927 (second lane), 23,636 (third lane), and 18,780 (far right
lane). To control for loading inequities the amount of SHPS-1 protein in
each lane is shown in the lower panel.
FIG. 4. SHP-2 recruitment to SHPS-1 in response to IGF-I stim-
ulation. Cells were grown to 90% confluence and then incubated over-
night in SFM. They were then exposed to 100 ng/ml IGF-I for various
lengths of time as indicated. After cell lysis and immunoprecipitation
(IP) with an anti-SHPS-1 antibody association of SHP-2 with SHPS-1
was visualized by Western immunoblotting (IB) using an anti-SHP-2
antibody. The results expressed as arbitrary scanning units are: 1,577
(left lane), 25,650 (center lane), and 2,070 (right lane). To control for
loading inequities the amount of SHPS-1 protein in each lane is shown
in the lower panel.
FIG. 5. SHP-2 recruitment to SHPS-1 in response to IGF-I stim-
ulation in cells expressing SHPS-1tr. A and B, expression of
SHPS-1 protein in cells transfected with either SHPS-1tr or the empty
vector alone. Cells were grown to 90% confluence and then incubated
overnight in SFM. After lysis and immunoprecipitation (IB) with the
anti-SHPS-1fl antibody the level of SHPS-1 protein was visualized by
Western immunoblotting (IB) with either the anti-SHPS-1fl antibody
(A) or with the anti SHPS-1tr antibody (B). C, cells transfected with
either SHPS-1tr or the empty vector alone were grown to 90% conflu-
ence and then incubated overnight in SFM. The cells were then exposed
to 100 ng/ml IGF-I for various lengths of time as indicated. After cell
lysis and immunoprecipitation with an anti-SHPS-1 antibody the asso-
ciation of SHP-2 was visualized by Western immunoblotting with an
anti-SHP-2 antibody. To control for loading inequities the amount of
SHPS-1 protein in each lane is shown in the lower panels.
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a Truncated Form of SHPS-1—To confirm that loss of SHPS-1
recruitment of SHP-2 would alter SHP-2 association with
IGF-IR we utilized the cells expressing the truncated form of
SHPS-1. In Fig. 6 it can be seen that after IGF-I stimulation
there was no recruitment of SHP-2 to the IGF-IR in cells
expressing the truncated form of SHPS-1. This blot was ex-
posed to film for 24 h to confirm that there was no SHP-2
association. Recruitment of SHP-2 to the IGF-IR in cells ex-
pressing the empty vector alone is also shown.
Altered IGF-IR Phosphorylation Time Course in Cells Ex-
pressing an Inactive Form of SHP-2—The rapid decrease in
SHPS-1 phosphorylation and loss of SHP-2 association with
SHPS-1 are consistent with phosphorylated SHPS-1 being a
substrate for SHP-2 phosphatase (18, 20). To prove that the
recruitment of SHP-2 to SHPS-1 and its subsequent release
were required for SHP-2 association with and dephosphoryl-
ation of the IGF-IR we expressed a catalytically inactive form of
SHP-2 (SHP-2 C-S), which cannot dephosphorylate SHPS-1.
We then examined the time course of IGF-IR dephosphoryl-
ation in these cells.
Fig. 7A shows that the transfected cells express FLAG-
tagged SHP-2 C-S and that the cells transfected with the empty
vector alone do not. In Fig. 7B, top panel, it can be seen that in
cells expressing the catalytically inactive form of SHP-2,
SHPS-1 was phosphorylated after 5 min of stimulation with
IGF-I; however, unlike cells that contain wild type SHP-2, cells
expressing the SHP-2 C-S mutant showed no decrease in
SHPS-1 phosphorylation at 10 min. Fig. 7B, middle panel,
demonstrates that in contrast to the cells transfected with the
empty vector alone, the cells expressing SHP-2 C-S showed no
dissociation of SHP-2 from SHPS-1 over the time course that
was examined. This was confirmed further by showing that
when IGF-I-R was immunoprecipitated followed by immuno-
blotting for SHP-2, no SHP-2 could be detected (data not
shown). This shows that retention of SHP-2 binding to SHPS-1
was associated with a loss of binding to the IGF-IR.
Fig. 7C shows that after a 5-min exposure to IGF-I, cells
expressing the C-S mutant or cells transfected with an empty
vector showed a marked increase in IGF-IR phosphorylation.
After 10 min there is a significant reduction in IGF-IR phos-
phorylation in the empty vector cells but no change in cells
expressing the C-S mutant, and these cells show a further
increase in receptor phosphorylation at the 20-min time point.
These data suggest that in the absence of SHP-2 release from
SHPS-1 there is no recruitment of SHP-2 to the IGF-IR and no
receptor dephosphorylation.
DISCUSSION
The increase in IGF-IR phosphorylation which occurs after
ligand binding is transient and is followed by a rapid decline in
the level of IGF-IR phosphorylation. Because there are no
significant changes in IGF-IR protein levels over this time this
suggests that there are activation and recruitment of a tyrosine
phosphatase to the receptor. In vitro studies have shown that a
catalytically inactive form of SHP-2 can bind directly to ty-
rosine-phosphorylated forms of both the insulin and IGF-IR
(10). Those studies suggested indirectly that SHP-2 could de-
phosphorylate both receptors after it bound because only a
phosphatase-inactive form of SHP-2 formed a stable complex
and did not dephosphorylate either receptor (10). From the
studies presented here we propose that the recruitment of
SHP-2 to the IGF-IR via SHPS-1 is responsible for the decrease
in IGF-IR phosphorylation after IGF-I-induced receptor activa-
tion and is therefore an important regulator of IGF-I signaling.
This was first suggested by our data demonstrating an associ-
ation between the time at which the IGF-IR phosphorylation
was decreasing and the time at which the SHP-2 phosphatase
associated with the receptor. This conclusion is supported fur-
ther by our data demonstrating that in cells expressing a trun-
cated form of SHPS-1, SHP-2 is not recruited to the IGF-IR and
by the detection of sustained IGF-IR phosphorylation in cells
FIG. 6. SHP-2 association with the IGF-IR in cells expressing
SHPS-1tr. Cells were grown to 90% confluence and then incubated
overnight in SFM. The cells were then exposed to 100 ng/ml IGF-I for
various lengths of time as indicated. After cell lysis and immunopre-
cipitation (IP) with an anti-IGF-IR antibody the association of SHP-2
with the receptor was visualized by Western immunoblotting (IB) with
an anti-SHP-2 antibody. To control for loading inequities the amount of
IGF-IR protein in each lane is shown in the lower panels.
FIG. 7. IGF-IR phosphorylation time course and SHP-2 recruit-
ment in cells expressing catalytically inactive SHP-2 (SHP-2
C-S). A, cells expressing SHP-2 C-S and cells transfected with the
empty vector alone were grown to 90% confluence and then incubated in
SFM overnight. After lysis and immunoprecipitation (IP) with an anti-
SHP-2 antibody the expression of FLAG-tagged protein was visualized
by Western immunoblotting (IB) with an anti-FLAG antibody. B, top
panel, cells transfected with either SHP2 C-S or the empty vector alone
were grown to 90% confluence and then incubated overnight in SFM.
Cells were then exposed to 100 ng/ml IGF-I for various lengths of time
as indicated. After cell lysis and immunoprecipitation with an anti-
SHPS-1 antibody, tyrosine phosphorylation was visualized by Western
immunoblotting with an anti-phosphotyrosine antibody. The results
expressed as arbitrary scanning units are: 11,378 (far left lane), 21,519
(second lane), 23,415 (third lane), 10,171 (fourth lane), 25,709 (fifth
lane), and 12,890 (far right lane). Middle panel, to control for loading
inequities the amount of SHPS-1 protein in each lane is shown. Bottom
panel, after immunoprecipitation with an anti-SHPS-1 antibody the
association of SHP-2 was visualized by Western immunoblotting with
an anti-SHP-2 antibody. The results expressed as arbitrary scanning
units are 14,337 (far left lane), 22,418 (second lane), 28,541 (third lane),
1,007 (fourth lane), 26,090 (fifth lane), 14,944 (far right lane). C, cells
transfected with either SHP2 C-S or the empty vector alone were grown
to 90% confluence then incubated overnight in SFM. Cells were then
exposed to 100 ng/ml IGF-I for various lengths of time as indicated.
After cell lysis and immunoprecipitation with an anti-IGF-IR antibody,
tyrosine phosphorylation of the IGF-IR was visualized by Western
immunoblotting with an antiphosphotyrosine antibody (RC20). The
results expressed as arbitrary scanning units are: 1,547 (far left lane),
10,519 (second lane), 12,177 (third lane), 19,030 (fourth lane), 2,999
(fifth lane), 26,514 (sixth lane), and 8,445 (far right lane). To control for
loading inequities the amount of IGF-IR protein in each lane is shown
in the lower panels.
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expressing the catalytically inactive form of SHP-2 which is not
released from SHPS-1.
SHPS-1 has recently been identified as a transmembrane
glycoprotein with three immunoglobulin-like domains, four po-
tential tyrosine phosphorylation sites, and SH-2 binding motifs
in its cytoplasmic domain (17–20). It has been shown to be
phosphorylated on tyrosines in response to ligand occupancy of
several growth factor receptors and the insulin receptor gener-
ating two high affinity binding sites for SHP-2 (17–20). Binding
of the two SH-2 domains within SHP-2 to these high affinity
binding sites on SHPS-1 increases SHP-2 association and acti-
vates the phosphatase by releasing the N-terminal SH-2 do-
main from constraining the phosphatase active site (25–27).
SHPS-1 phosphorylation not only provides a binding site for
SHP-2, but it is also a substrate for the phosphatase, resulting
in dephosphorylation of SHPS-1 and therefore loss of the
SHP-2 binding sites (18, 20). It has been proposed that once
SHP-2 has been recruited to SHPS-1, after its activation and
the subsequent dephosphorylation of SHPS-1, it is available to
associate with other plasma membrane-associated proteins
(21, 22). As has been shown for the insulin, platelet-derived
growth factor, and the epidermal growth factor receptors (16),
we show here that IGF-I can stimulate an increase in SHPS-1
phosphorylation, and this results in an increase in the associ-
ation of SHP-2. The time course of maximal SHPS-1 phos-
phorylation and SHP-2 recruitment after IGF-I stimulation
precedes maximal IGF-IR phosphorylation and SHP-2 recruit-
ment by the receptor. This further supports the conclusion that
recruitment of SHP-2 to the IGF-IR via SHPS-1 is the mecha-
nism by which SHP-2 is recruited to the receptor. This conclu-
sion is strongly supported by our data showing that in cells
expressing a truncated form of SHPS-1, in which the two ty-
rosines (Tyr449 and Tyr475) that are known to be the binding
site for SHP-2 have been deleted (21), SHP-2 is not recruited to
either SHPS-1 or to the IGF-IR. The importance of the release
of SHP-2 from SHPS-1 is substantiated further by the data
demonstrating a lack of SHP-2 recruitment to the IGF-IR in
cells expressing the catalytically inactive form of SHP-2. In
these cells SHPS-1 is not dephosphorylated, SHP-2 is not re-
leased, and IGF-IR phosphorylation is prolonged. Thus stimu-
lation of SHPS-1 phosphorylation after ligand occupancy of
IGF-IR and the subsequent dephosphorylation of SHPS-1 by
SHP-2 are critical steps that are required for the IGF-IR de-
phosphorylation response to be initiated.
SHP-2 has been shown to bind various signaling molecules
and depending upon the molecule and the experimental ap-
proach taken, it has been shown to have both positive and
negative effects on signaling by intracellular mediators that
have been activated by tyrosine kinase receptors. Expression of
a mutated form of IRS-1 which does not bind SHP-2 results in
enhanced insulin-stimulated tyrosine phosphorylation of
IRS-1, which in turn increased the association of PI-3 kinase
with IRS-1 and enhanced insulin-stimulated protein synthesis
(28). Similarly, mutation of the SHP-2 binding site in the GH
receptor prolongs GH-stimulated tyrosine phosphorylation of
the GH receptor and the signaling proteins JAK2 and STAT 5B
(29). Overexpression of SHPS-1 has been shown to result in a
decrease in insulin-stimulated DNA synthesis, and this result
was attributed to its phosphorylation and recruitment of
SHP-2 (19). However, other studies using dominant negative
mutants and anti-SHP-2 antibodies have suggested that SHP-2
may play an important positive role in IGF-I and other growth
factor-stimulated cell proliferation through activation of mito-
gen-activated protein kinase, although the signaling compo-
nents that are dephosphorylated by SHP-2 which mediate
these effects have not been identified (20, 21, 29–33). This
appears to occur upstream of RAS activation and at least for
some growth factors involves SHP-2 recruitment to GAB-1-like
tyrosine-phosphorylated docking proteins (24) and/or its bind-
ing to Grb2 (34, 35, 36). It would seem therefore that SHP-2 can
play a dual role in growth factor signaling, and its activity
would appear to be dependent upon its subcellular localization
and binding partners. However, as demonstrated in our studies
the IGF-IR and a previously published study for the GH recep-
tor (22), SHP-2 recruitment to SHPS-1 clearly contributes to
the ability of SHP-2 to effect receptor dephosphorylation.
Because it has been shown previously that integrin ligand
occupancy can regulate SHP-2 localization and activation (17,
18, 37, 38), our findings suggest that its association with the
IGF-IR may also be regulated by integrin occupancy. The reg-
ulation of SHP-2 association with the IGF-IR and hence IGF-IR
phosphorylation levels by V3 ligand occupancy is an attrac-
tive hypothesis to explain our observation that blocking V3
ligand occupancy reduces IGF-IR phosphorylation (39). Identi-
fication of factors other than SHPS-1 which regulate SHP-2
subcellular localization and therefore its binding partners and
activation action will be important for understanding the role
of other variables such as V3 integrin ligand occupancy in
regulating IGF-I signaling.
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